2
Total investments
0
Early stage
2
Mid stage
0
Late stage
3y
Years active
Portfolio
2 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Board Member / Investor
Aug 2024
ATANIS Biotech AG has developed a novel functional cell based assay that massively simplifies the diagnosis of allergies and can predict treatment success of therapies. This test is used to assess safety and efficacy of potential new drug candidates for allergy treatment. It is being developed for an upcoming commercialization in the clinic.
Contact us at: info@atanis-biotech.com
Board Member / Investor (seed round)
Sep 2023
We leverage our expertise to design and built time-of-flight mass spectrometers (TOF-MS) bringing space technology to Earth. Our instruments are compact, robust and bring the leading edge to industrial process analyses. Our focus is semiconductor manufacturing and the issues of process engineers at end-users (foundries) and OEMs (wafer fab equipment). Our products redefine real-time analysis of gases and enable higher process efficiency with lower scrap rates and therefore better overall yields.
Experience · 3 entries
All (3)
Investments (2)
Board (2)
2024
Board Member / Investor
Aug 2024
ATANIS Biotech AG has developed a novel functional cell based assay that massively simplifies the diagnosis of allergies and can predict treatment success of therapies. This test is used to assess safety and efficacy of potential new drug candidates for allergy treatment. It is being developed for an upcoming commercialization in the clinic.
Contact us at: info@atanis-biotech.com
2023
Board Member / Investor (seed round)
Sep 2023
We leverage our expertise to design and built time-of-flight mass spectrometers (TOF-MS) bringing space technology to Earth. Our instruments are compact, robust and bring the leading edge to industrial process analyses. Our focus is semiconductor manufacturing and the issues of process engineers at end-users (foundries) and OEMs (wafer fab equipment). Our products redefine real-time analysis of gases and enable higher process efficiency with lower scrap rates and therefore better overall yields.
2011
Analyst (Student) in Private Equity Team
2011
HBM Partners was founded in 2001 with the goal to invest in private and public emerging biopharma and other healthcare-related companies.
HBM Partners has a team of experienced professionals to source, analyse and engage in investments in biopharma, medical devices and diagnostics industries. HBM Partners has a track-record of over 100 investments that resulted so far in significant value creation by more than 60 trade sales and IPOs since inception.
HBM Partners is regulated by FINMA and advises SIX listed HBM Healthcare Investments and further specialised public and private equity investment products.